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Once you have Acrobat Reader open on your computer, click on the Comment tab at the right of the toolbar: 
 
 
 
 
 
This will open up a panel down the right side of the document. The majority of 
tools you will use for annotating your proof will be in the Annotations section, 
pictured opposite. We’ve picked out some of these tools below: 
 
 
 
 
 
 
 
 
 
1. Replace (Ins) Tool – for replacing text. 
 
 
Strikes a line through text and opens up a text 
box where replacement text can be entered. 
 
How to use it 
 
• Highlight a word or sentence. 
• Click on the Replace (Ins) icon in the Annotations 
section. 
• Type the replacement text into the blue box that 
appears. 
2. Strikethrough (Del) Tool – for deleting text. 
 
 
Strikes a red line through text that is to be 
deleted. 
 
How to use it 
 
• Highlight a word or sentence. 
• Click on the Strikethrough (Del) icon in the 
Annotations section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Add note to text Tool – for highlighting a section 
to be changed to bold or italic. 
 
 
Highlights text in yellow and opens up a text 
box where comments can be entered. 
 
How to use it 
 
• Highlight the relevant section of text. 
• Click on the Add note to text icon in the 
Annotations section. 
• Type instruction on what should be changed 
regarding the text into the yellow box that 
appears. 
4. Add sticky note Tool – for making notes at 
specific points in the text. 
 
 
Marks a point in the proof where a comment 
needs to be highlighted. 
 
How to use it 
 
• Click on the Add sticky note icon in the 
Annotations section. 
• Click at the point in the proof where the comment 
should be inserted. 
• Type the comment into the yellow box that 
appears. 
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5. Attach File Tool – for inserting large amounts of 
text or replacement figures. 
 
 
Inserts an icon linking to the attached file in the 
appropriate place in the text. 
 
How to use it 
 
• Click on the Attach File icon in the Annotations 
section. 
• Click on the proof to where you’d like the attached 
file to be linked. 
• Select the file to be attached from your computer 
or network. 
• Select the colour and type of icon that will appear 
in the proof. Click OK. 
6. Drawing Markups Tools – for drawing 
shapes, lines and freeform annotations on 
proofs and commenting on these marks. 
Allows shapes, lines and freeform annotations to be 
drawn on proofs and for comment to be made on 
these marks.  
 
 
 
 
How to use it 
•  Click on one of the shapes in the Drawing Markups 
section. 
•  Click on the proof at the relevant point and draw the 
selected shape with the cursor. 
•  To add a comment to the drawn shape, move the 
cursor over the shape until an arrowhead appears. 
•  Double click on the shape and type any text in the 
red box that appears. 
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Most cases of encephalitis are caused by either viral infec-
tion or an antibody-mediated process, although in virtually
all studies a high proportion of patients have no aetiologi-
cal diagnosis. Recently, the diagnosis and management of
encephalitis has become more complex, with the awareness
that herpes simplex virus encephalitis (HSE) can be associ-
ated with a secondary anti-N-methyl-D-aspartate receptor
(anti-NMDAR) encephalitis. There is early evidence of
inflammatory mediators being distinct between infective
and antibody-mediated encephalitis.1 However, the number
of patients is small, and no studies have examined host
responses in anti-NMDAR encephalitis following HSE.
Two complementary studies add to this evolving story.
Nosadini et al. review the literature on the association
between HSE and anti-NMDAR encephalitis.2 Kothur
et al. extend insight into host inflammatory responses in
viral and antibody-mediated encephalitis, including one
case of HSE-induced anti-NMDAR encephalitis.3
Nosadini et al. succinctly summarize the literature on
anti-NMDAR encephalitis associated with HSE in adults
and children.2 Forty-three patients were identified, includ-
ing a newly reported case. Overall, the secondary
anti-NMDAR phase was associated more frequently with
movement disorders and less with seizures than the initial
infective phase. These features may be useful in clinically
distinguishing autoimmune from active viral encephalitis.
The authors also reviewed patients with HSE in whom
anti-NMDAR antibodies were detected retrospectively.
There is controversy as to whether these antibodies, often of
subclasses other than IgG, are driving clinical symptoms and
whether these subclasses are truly pathogenic. A number of
patients also had HSV detected by PCR in cerebrospinal
fluid (CSF) during a clinical episode of anti-NMDAR
encephalitis: again the clinical significance of this is
uncertain. The review highlights the need for better under-
standing of these conditions and how they interact.
Kothur et al. measured a panel of CSF chemokines and
cytokines in a child with HSE induced anti-NMDAR
encephalitis during acute admission and recovery, and
compared patterns of abundance with children suffering
chronic or relapsing HSE, pure anti-NMDAR encephalitis
and controls.3
Most of the assayed cyto/chemokines were elevated in
acute HSE, while in the post-HSE anti-NMDAR phase
there was persistent elevation of a few key mediators.
Interestingly, the cyto/chemokine elevation in the HSE/
NMDAR case was more florid than in anti-NMDAR
encephalitis alone. Most patients with chronic or relapsing
HSE showed persistent mediator elevation, suggesting
ongoing neuroinflammation, supported by histopathologi-
cal evidence in one patient. Nevertheless, some patients
had a response to immune therapy. This study underlines
the potential of examining host responses to gain insight
into the role of inflammation during encephalitic illness.
The rapid development of transcriptomic and proteomic
approaches offers an opportunity to identify specific
patterns of biomarkers involved in infective and antibody-
mediated encephalitis. Such techniques are already
beginning to provide insight into mechanisms of injury
and identify potential adjunctive treatments for HSE.4
The most effective treatment for antibody-mediated
encephalitis remains unknown. A range of immune thera-
pies are currently used, and management is non-standar-
dized and based on limited evidence.5 Currently,
evaluating treatment response relies on clinical symptoms
and antibody levels in serum or CSF. Antibody titres do
not reliably predict treatment response,6 and poor outcome
or relapse can occur despite low levels. There is a need for
accurate markers of disease activity to enable more person-
alized immune therapy.
Biological agents (e.g. anti-TNF therapy) are increas-
ingly used to treat extracranial autoimmune disorders. As
yet, it is unclear which (if any) biologic will reduce relapse
and morbidity in encephalitis. There is a need for well-
conducted trials to address the management of these con-
ditions. Host responses in brain inflammation could act as
proxy markers of treatment response, or even provide
potential therapeutic targets for host-directed therapies.
Specific host response patterns that distinguish antibody-
mediated from infective encephalitis would guide and
rationalize investigation. This would enable clinicians to
initiate appropriate treatment more promptly, benefiting
patients.
With the analysis of larger, well-defined patient cohorts,
further innovative longitudinal studies should aim to char-
acterize host response patterns to enable stratification of
patients into aetiological and prognostic categories, includ-
ing patients with HSE at risk of developing secondary
anti-NMDAR encephalitis. Paediatric and adult researchers
should pool their clinical resources to gain better under-
standing and develop new treatments for these devastating
conditions.
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